CN114949332A - Treating agent for rapidly promoting wound hemostasis and preparation method thereof - Google Patents
Treating agent for rapidly promoting wound hemostasis and preparation method thereof Download PDFInfo
- Publication number
- CN114949332A CN114949332A CN202210397809.7A CN202210397809A CN114949332A CN 114949332 A CN114949332 A CN 114949332A CN 202210397809 A CN202210397809 A CN 202210397809A CN 114949332 A CN114949332 A CN 114949332A
- Authority
- CN
- China
- Prior art keywords
- solution
- promoting wound
- rapidly promoting
- wound hemostasis
- treating agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/043—Mixtures of macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0015—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0036—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/02—Surgical adhesives or cements; Adhesives for colostomy devices containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/21—Acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
- A61L2300/624—Nanocapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Surgery (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a preparation method of a treating agent for rapidly promoting wound hemostasis, which comprises the following steps: uniformly mixing a chitosan solution, a polyvinyl alcohol/sodium alginate composite aqueous solution and a catalyst, adding glutaraldehyde to react for 1-3h at 50-60 ℃ under a stirring state, adding absolute ethyl alcohol to continue stirring, adjusting the system to be neutral, freezing, recovering to room temperature, soaking in a calcium chloride ethanol solution, ultrasonically cleaning, drying, and sterilizing to obtain a porous section; dissolving tris (hydroxymethyl) aminomethane in water, adjusting the pH value of the system to 8-8.4, adding tannic acid, stirring uniformly, immersing the porous section in the tannic acid, carrying out ultrasonic treatment for 1-2h, carrying out ultrasonic power of 300-400W, carrying out ultrasonic temperature of 40-50 ℃, taking out, washing with deionized water for 1-3 times, drying, immersing in a nanoparticle mixed solution, standing at room temperature for 10-20h, taking out, and drying to obtain the treating agent for rapidly promoting wound hemostasis.
Description
Technical Field
The invention relates to the technical field of hemostasis, in particular to a treating agent for rapidly promoting wound hemostasis and a preparation method thereof.
Background
Medical dressings are used extensively as coverings for wounds, and medical materials for covering sores, wounds, or other lesions. In the process of wound healing, the medical dressing can replace damaged skin to play a role of temporary barrier, so that wound infection is avoided or controlled, and an environment beneficial to wound healing is provided. Along with the understanding of the healing process of the wound surface, people have made continuous improvement and development of medical wound surface dressings. The novel dressing for wound nursing is revolutionarily changed nowadays, and a plurality of medical dressings with different performances can be selected by clinical nursing personnel.
In medical dressings, the hemostatic material has the obvious advantages of convenient use, suitability for different wound sizes and bleeding parts and the like, and is favored in hemostatic articles. In the existing various hemostatic materials, the main properties of the hemostatic materials are fabric-shaped, non-woven fabric, hydrogel and powder, and except the powdery hemostatic materials, the effect of the other shaped materials is difficult to improve when the materials treat large bleeding wounds in emergency departments. At present, powdery starch-based materials are widely used as hemostatic materials due to the characteristics of good biological safety, high water absorption, degradability and the like, but the original particle sizes of the powdery starch-based materials are generally distributed in the range of 10-50 mu m, and the particle sizes of most particles are below 30 mu m.
The chitosan is prepared by deacetylation extraction of chitin widely existing in marine organisms, microorganisms, shells of crustaceans and insect shells, has a chemical name of beta- (1,4) -2-acetamido-2-deoxy-D-glucan, and is a natural high-molecular linear polysaccharide with rich content. Because of good biocompatibility, antibacterial agent and oxidation resistance, chitosan has been widely used in the field of biomedical materials. The chitosan is rich in positively charged amino groups in the chemical structure, so that erythrocyte aggregation and negatively charged protein can be attracted in the hemostasis process, the coagulation process can be effectively promoted, and the chitosan has strong adhesion after contacting with blood, so that the wound can be protected. But it can hardly stick to the narrow bleeding opening due to the rigid characteristics, and can not completely realize effective hemostasis in emergency situations of emergency department.
The polyvinyl alcohol sponge is a swellable medical material and is mainly used for wound treatment, nursing and closed negative pressure drainage. The polyvinyl alcohol sponge does not have the function of hemostasis, and the hemostasis is mainly realized by the physical compression effect generated by the local rapid blood absorption and swelling. It is dependent only on physical action, so it has not good effect for curing hemorrhage.
The composite compressed hemostatic sponge prepared by directly compounding the polyvinyl alcohol and the chitosan is absorbed and swelled by the polyvinyl alcohol sponge, so that the rigid chitosan is easy to fall off, and in the using process, the chitosan falls off to block pore passages of the hemostatic sponge, so that the imbibition swelling performance of the hemostatic sponge is influenced, and the risk of secondary bleeding is easily caused.
Disclosure of Invention
The invention aims to solve the defects in the prior art and provides a treating agent for rapidly promoting wound hemostasis and a preparation method thereof.
A preparation method of a treating agent for rapidly promoting wound hemostasis comprises the following steps:
step 1, uniformly mixing a chitosan solution, a polyvinyl alcohol/sodium alginate composite aqueous solution and a catalyst, adding glutaraldehyde to react for 1-3h at 50-60 ℃ under a stirring state, adding absolute ethyl alcohol to continue stirring, adjusting a system to be neutral, adding the mixture into a mold, freezing for 1-2h at-20 to-40 ℃, recovering to room temperature, soaking in a calcium chloride ethanol solution for 1-4h, ultrasonically cleaning, drying and sterilizing to obtain a porous section;
and 2, dissolving the tris (hydroxymethyl) aminomethane in water, adjusting the pH value of the system to 8-8.4, adding tannic acid, uniformly stirring, immersing the porous section in the solution, performing ultrasonic treatment for 1-2 hours, performing ultrasonic power of 300-400W, performing ultrasonic temperature of 40-50 ℃, taking out, washing with deionized water for 1-3 times, drying, immersing in a nanoparticle mixed solution, standing at room temperature for 10-20 hours, taking out, and drying to obtain the treating agent for rapidly promoting wound hemostasis.
Preferably, in the step 1, the chitosan solution is obtained by adding chitosan into an acidic solution and uniformly stirring.
Preferably, the acidic solution is an aqueous solution of at least one of acetic acid, citric acid or malic acid.
Preferably, in the step 1, the polyvinyl alcohol/sodium alginate composite aqueous solution is prepared by adding vinyl alcohol and sodium alginate into water and stirring until the polyvinyl alcohol and the sodium alginate are completely dissolved.
Preferably, in the step 1, the mass ratio of the chitosan, the polyvinyl alcohol, the sodium alginate, the catalyst and the glutaraldehyde is 10-20: 5-15: 1-5: 0.01-0.1: 1-2.
Preferably, in step 1, the catalyst is at least one of hydrochloric acid, sulfuric acid, acetic acid and phosphoric acid.
Preferably, in the step 1, the mass fraction of the calcium chloride ethanol solution is 0.8-1.2%.
Preferably, in the step 2, the mass ratio of the trihydroxymethyl aminomethane, the tannic acid and the water is 1-2: 1-2: 80-100.
Preferably, in the step 2, hydrochloric acid with the concentration of 0.5-1.5mol/L is used for adjusting the pH value of the system to 8-8.4.
Preferably, in step 2, the nanoparticle mixed solution is prepared by adding ursodeoxycholic acid and polyethyleneimine into dimethyl sulfoxide for uniform mixing, and then dialyzing in deionized water.
Preferably, the mass ratio of the ursodeoxycholic acid to the polyethyleneimine to the dimethyl sulfoxide is 1-4: 1-2: 30-60.
Preferably, in the step 2, in the nanoparticle mixed solution, the particle size of the nanoparticles is 150-200nm, and the Zeta potential is 60-70 mV.
A treating agent for rapidly promoting wound hemostasis is prepared by adopting the preparation method of the treating agent for rapidly promoting wound hemostasis.
The technical effects of the invention are as follows:
(1) according to the invention, polyvinyl alcohol and chitosan are subjected to blending crosslinking reaction, then absolute ethyl alcohol is added, the absolute ethyl alcohol is dispersed in the system, and the polyvinyl alcohol and the chitosan are not dissolved in the absolute ethyl alcohol, so that a large number of fine through holes are formed in a crosslinking structure, and a crosslinking network structure is formed by ion exchange between calcium ions and sodium ions of sodium alginate, so that a dual interpenetrating three-dimensional network structure is formed, the mechanical property of the structure is effectively enhanced, the adsorption performance is extremely excellent, and the treatment effect on wounds is excellent.
(2) In an alkaline ultrasonic environment, tannic acid carries out self-assembly polymerization on the surface of the porous section bar and the inside of the porous section bar, a negatively charged structure layer is provided for the adsorption and deposition of nanoparticles in a nanoparticle mixed solution, and meanwhile, the tannic acid has strong affinity with the porous section bar due to the fact that the tannic acid contains abundant phenol groups in the structure, and the tannic acid and the porous section bar are high in mutual combination degree; the ursodeoxycholic acid and the polyethyleneimine are self-assembled to form cationic nanoparticles, so that platelet activation and aggregation can be effectively induced, and rapid hemostasis is realized; the invention activates the blood platelet with negative electricity through coulomb force, induces the blood platelet aggregation, accelerates the blood coagulation process, and the active component remained at the wound part can still continue to play a role even after the treating agent is removed.
(3) The invention has extremely high elasticity and excellent flexibility, can deal with bleeding of deep, narrow and non-compressible wounds, has high degree of fitting with the wounds, can quickly absorb liquid and expand at the wounds, has the functions of effectively promoting erythrocyte aggregation and activating blood platelets, doubly accelerates the coagulation process, has good biocompatibility, does not need to be debrided immediately after hemostasis is finished, and avoids the risk of secondary bleeding.
Detailed Description
The present invention will be further illustrated with reference to the following specific examples.
Example 1
A preparation method of a treating agent for rapidly promoting wound hemostasis comprises the following steps:
step 1, adding 10kg of chitosan into 30kg of acetic acid solution with the concentration of 0.5mol/L, and uniformly stirring to obtain a chitosan solution;
adding 5kg of polyvinyl alcohol and 1kg of sodium alginate into 20kg of water, and stirring until the polyvinyl alcohol and the sodium alginate are completely dissolved to obtain a polyvinyl alcohol/sodium alginate composite aqueous solution;
uniformly mixing a chitosan solution, a polyvinyl alcohol/sodium alginate composite aqueous solution and 0.01kg of hydrochloric acid, adding 1kg of glutaraldehyde to react for 1h at 50 ℃ under the stirring state, stirring at the speed of 400r/min, adding 3kg of absolute ethyl alcohol, continuously stirring for 10min, adjusting a system to be neutral by using a sodium hydroxide solution with the concentration of 0.5mol/L, adding the sodium hydroxide solution into a mold, freezing at the temperature of minus 20 ℃ for 1h, recovering to the room temperature, soaking in a calcium chloride ethanol solution with the mass fraction of 0.8% for 1h, ultrasonically cleaning for 1 time by using the absolute ethyl alcohol, drying and sterilizing to obtain a porous section;
step 2, adding 1kg of ursodeoxycholic acid and 1kg of polyethyleneimine into 30kg of DMSO, uniformly mixing, and dialyzing in deionized water to obtain a nanoparticle mixed solution; the particle size of the nanoparticles in the nanoparticle mixed solution is 150-200nm, and the Zeta potential is 60.3 mV;
dissolving 1kg of tris (hydroxymethyl) aminomethane in 80kg of water, adjusting the pH value of the system to 8-8.4 by using hydrochloric acid with the concentration of 0.5mol/L, adding 1kg of tannic acid, uniformly stirring, immersing the porous section in the hydrochloric acid, carrying out ultrasonic treatment for 1 hour with the ultrasonic power of 300W and the ultrasonic temperature of 40 ℃, taking out, washing with deionized water for 1 time, drying, immersing in a nanoparticle mixed solution, standing at room temperature for 10 hours, taking out, and drying to obtain the treatment agent for rapidly promoting wound hemostasis.
Example 2
A preparation method of a treating agent for rapidly promoting wound hemostasis comprises the following steps:
step 1, adding 20kg of chitosan into 50kg of acetic acid solution with the concentration of 1.2mol/L, and uniformly stirring to obtain a chitosan solution;
adding 15kg of polyvinyl alcohol and 5kg of sodium alginate into 40kg of water, and stirring until the polyvinyl alcohol and the sodium alginate are completely dissolved to obtain a polyvinyl alcohol/sodium alginate composite aqueous solution;
uniformly mixing a chitosan solution, a polyvinyl alcohol/sodium alginate composite aqueous solution and 0.1kg of acetic acid, adding 2kg of glutaraldehyde to react for 3 hours at 60 ℃ under a stirring state, stirring at the speed of 600r/min, adding 10kg of absolute ethyl alcohol, continuously stirring for 20 minutes, adjusting a system to be neutral by using a sodium hydroxide solution with the concentration of 1.2mol/L, adding the sodium hydroxide solution into a mold, freezing at the temperature of minus 40 ℃ for 2 hours, recovering to room temperature, soaking in a calcium chloride ethanol solution with the mass fraction of 1.2% for 4 hours, ultrasonically cleaning for 3 times by using the absolute ethyl alcohol, drying and sterilizing to obtain a porous section;
step 2, adding 4kg of ursodeoxycholic acid and 2kg of polyethyleneimine into 60kg of DMSO, uniformly mixing, and dialyzing in deionized water to obtain a nanoparticle mixed solution; the particle size of the nanoparticles in the nanoparticle mixed solution is 150-200nm, and the Zeta potential is 69.3 mV;
dissolving 2kg of tris (hydroxymethyl) aminomethane in 100kg of water, adjusting the pH value of the system to 8-8.4 by using hydrochloric acid with the concentration of 1.5mol/L, adding 2kg of tannic acid, uniformly stirring, immersing the porous section in the hydrochloric acid, carrying out ultrasonic treatment for 2 hours with the ultrasonic power of 400W and the ultrasonic temperature of 50 ℃, taking out, washing with deionized water for 3 times, drying, immersing in a nanoparticle mixed solution, standing at room temperature for 20 hours, taking out, and drying to obtain the treating agent for rapidly promoting wound hemostasis.
Example 3
A preparation method of a treating agent for rapidly promoting wound hemostasis comprises the following steps:
step 1, adding 13kg of chitosan into 45kg of acetic acid solution with the concentration of 0.6mol/L, and uniformly stirring to obtain a chitosan solution;
adding 12kg of polyvinyl alcohol and 2kg of sodium alginate into 35kg of water, and stirring until the polyvinyl alcohol and the sodium alginate are completely dissolved to obtain a polyvinyl alcohol/sodium alginate composite aqueous solution;
uniformly mixing a chitosan solution, a polyvinyl alcohol/sodium alginate composite aqueous solution and 0.02kg of sulfuric acid, adding 1.3kg of glutaraldehyde to react for 2.5 hours at 57 ℃ under the stirring state, adding 8kg of absolute ethyl alcohol to continue stirring for 13 minutes, adjusting a system to be neutral by adopting a sodium hydroxide solution with the concentration of 1mol/L, adding the sodium hydroxide solution into a mold, freezing at the temperature of minus 25 ℃ for 1.7 hours, recovering to the room temperature, soaking in a calcium chloride ethanol solution with the mass fraction of 0.9% for 3 hours, ultrasonically cleaning with absolute ethyl alcohol for 2 times, drying and sterilizing to obtain a porous section;
step 2, adding 2kg of ursodeoxycholic acid and 1.8kg of polyethyleneimine into 40kg of DMSO, uniformly mixing, and dialyzing in deionized water to obtain a nanoparticle mixed solution; the particle size of the nanoparticles in the nanoparticle mixed solution is 150-200nm, and the Zeta potential is 66.6 mV;
dissolving 1.3kg of tris (hydroxymethyl) aminomethane in 95kg of water, adjusting the pH value of a system to be 8-8.4 by adopting hydrochloric acid with the concentration of 0.8mol/L, adding 1.7kg of tannic acid, uniformly stirring, immersing the porous section in the hydrochloric acid, carrying out ultrasonic treatment for 1.3h, wherein the ultrasonic power is 380W, the ultrasonic temperature is 42 ℃, taking out, washing for 2 times by using deionized water, drying, immersing in a nanoparticle mixed solution, standing for 17h at room temperature, taking out, and drying to obtain the treating agent for rapidly promoting wound hemostasis.
Example 4
A preparation method of a treating agent for rapidly promoting wound hemostasis comprises the following steps:
step 1, adding 17kg of chitosan into 35kg of acetic acid solution with the concentration of 1mol/L, and uniformly stirring to obtain a chitosan solution;
adding 8kg of polyvinyl alcohol and 4kg of sodium alginate into 25kg of water, and stirring until the polyvinyl alcohol and the sodium alginate are completely dissolved to obtain a polyvinyl alcohol/sodium alginate composite aqueous solution;
uniformly mixing a chitosan solution, a polyvinyl alcohol/sodium alginate composite aqueous solution and 0.08kg of phosphoric acid, adding 1.7kg of glutaraldehyde to react for 1.5h at 53 ℃ under a stirring state, stirring at 550r/min, adding 4kg of absolute ethyl alcohol, continuously stirring for 17min, adjusting a system to be neutral by using a sodium hydroxide solution with the concentration of 0.6mol/L, adding the sodium hydroxide solution into a mold, freezing at-35 ℃ for 1.3h, recovering to room temperature, soaking in a calcium chloride ethanol solution with the mass fraction of 1.1% for 2h, ultrasonically cleaning for 2 times by using the absolute ethyl alcohol, drying, and sterilizing to obtain a porous section;
step 2, adding 3kg of ursodeoxycholic acid and 1.2kg of polyethyleneimine into 50kg of DMSO, uniformly mixing, and dialyzing in deionized water to obtain a nanoparticle mixed solution; the particle size of the nanoparticles in the nanoparticle mixed solution is 150-200nm, and the Zeta potential is 61.7 mV;
dissolving 1.7kg of tris (hydroxymethyl) aminomethane in 85kg of water, adjusting the pH value of a system to be 8-8.4 by adopting hydrochloric acid with the concentration of 1.2mol/L, adding 1.3kg of tannic acid, uniformly stirring, immersing the porous section in the hydrochloric acid, carrying out ultrasonic treatment for 1.7h, wherein the ultrasonic power is 320W, the ultrasonic temperature is 48 ℃, taking out, washing for 2 times by using deionized water, drying, immersing in a nanoparticle mixed solution, standing for 13h at room temperature, taking out, and drying to obtain the treating agent for rapidly promoting wound hemostasis.
Example 5
A preparation method of a treating agent for rapidly promoting wound hemostasis comprises the following steps:
step 1, adding 15kg of chitosan into 40kg of acetic acid solution with the concentration of 0.8mol/L, and uniformly stirring to obtain a chitosan solution;
adding 10kg of polyvinyl alcohol and 3kg of sodium alginate into 30kg of water, and stirring until the polyvinyl alcohol and the sodium alginate are completely dissolved to obtain a polyvinyl alcohol/sodium alginate composite aqueous solution;
uniformly mixing a chitosan solution, a polyvinyl alcohol/sodium alginate composite aqueous solution and 0.05kg of phosphoric acid, adding 1.5kg of glutaraldehyde to react for 2 hours at 55 ℃ under the stirring state, stirring at 500r/min, adding 6kg of absolute ethyl alcohol, continuously stirring for 15 minutes, adjusting a system to be neutral by using a sodium hydroxide solution with the concentration of 0.8mol/L, adding the sodium hydroxide solution into a mold, freezing at-30 ℃ for 1.5 hours, recovering to room temperature, soaking in a calcium chloride ethanol solution with the mass fraction of 1% for 2.5 hours, ultrasonically cleaning for 2 times by using the absolute ethyl alcohol, drying and sterilizing to obtain a porous section;
step 2, adding 2.5kg of ursodeoxycholic acid and 1.5kg of polyethyleneimine into 45kg of DMSO, uniformly mixing, and dialyzing in deionized water to obtain a nanoparticle mixed solution; the particle size of the nanoparticles in the nanoparticle mixed solution is 150-200nm, and the Zeta potential is 64.7 mV;
dissolving 1.5kg of tris (hydroxymethyl) aminomethane in 90kg of water, adjusting the pH value of the system to 8-8.4 by using hydrochloric acid with the concentration of 1mol/L, adding 1.5kg of tannic acid, stirring uniformly, immersing the porous section in the hydrochloric acid, carrying out ultrasonic treatment for 1.5h, wherein the ultrasonic power is 350W, the ultrasonic temperature is 45 ℃, taking out, washing for 2 times by using deionized water, drying, immersing in a nanoparticle mixed solution, standing for 15h at room temperature, taking out, and drying to obtain the treating agent for rapidly promoting wound hemostasis.
Comparative example 1
A preparation method of a wound hemostasis treating agent comprises the following steps:
step 1, adding 15kg of chitosan into 40kg of acetic acid solution with the concentration of 0.8mol/L, and uniformly stirring to obtain a chitosan solution;
adding 13kg of polyvinyl alcohol into 30kg of water, and stirring until the polyvinyl alcohol and the sodium alginate are completely dissolved to obtain a polyvinyl alcohol/sodium alginate composite aqueous solution;
uniformly mixing a chitosan solution, a polyvinyl alcohol/sodium alginate composite aqueous solution and 0.05kg of phosphoric acid, adding 1.5kg of glutaraldehyde to react for 2 hours at the temperature of 55 ℃ under the stirring state, adding 6kg of absolute ethyl alcohol to continue stirring for 15 minutes, adjusting a system to be neutral by adopting a sodium hydroxide solution with the concentration of 0.8mol/L, adding the sodium hydroxide solution into a mold, freezing the mixture at the temperature of minus 30 ℃ for 1.5 hours, recovering to the room temperature, ultrasonically cleaning the mixture for 2 times by adopting the absolute ethyl alcohol, drying and sterilizing the mixture to obtain a porous section;
step 2, adding 2.5kg of ursodeoxycholic acid and 1.5kg of polyethyleneimine into 45kg of DMSO, uniformly mixing, and dialyzing in deionized water to obtain a nanoparticle mixed solution; the particle size of the nanoparticles in the nanoparticle mixed solution is 150-200nm, and the Zeta potential is 64.7 mV;
dissolving 1.5kg of tris (hydroxymethyl) aminomethane in 90kg of water, adjusting the pH value of the system to 8-8.4 by using hydrochloric acid with the concentration of 1mol/L, adding 1.5kg of tannic acid, uniformly stirring, immersing the porous section in the solution, carrying out ultrasonic treatment for 1.5h, wherein the ultrasonic power is 350W, the ultrasonic temperature is 45 ℃, taking out, washing for 2 times by using deionized water, drying, immersing in a nanoparticle mixed solution, standing for 15h at room temperature, taking out, and drying to obtain the wound hemostasis treating agent.
Comparative example 2
A preparation method of a wound hemostasis treating agent comprises the following steps:
step 1, adding 15kg of chitosan into 40kg of acetic acid solution with the concentration of 0.8mol/L, and uniformly stirring to obtain a chitosan solution;
adding 10kg of polyvinyl alcohol and 3kg of sodium alginate into 30kg of water, and stirring until the polyvinyl alcohol and the sodium alginate are completely dissolved to obtain a polyvinyl alcohol/sodium alginate composite aqueous solution;
uniformly mixing a chitosan solution, a polyvinyl alcohol/sodium alginate composite aqueous solution and 0.05kg of phosphoric acid, adding 1.5kg of glutaraldehyde into the mixture at 55 ℃ under the stirring state for reacting for 2 hours, wherein the stirring speed is 500r/min, adding 6kg of absolute ethyl alcohol, continuously stirring for 15 minutes, adjusting the system to be neutral by adopting a sodium hydroxide solution with the concentration of 0.8mol/L, adding the sodium hydroxide solution into a mold, freezing the mixture at the temperature of-30 ℃ for 1.5 hours, recovering the temperature to the room temperature, soaking the mixture in a calcium chloride ethanol solution with the mass fraction of 1% for 2.5 hours, ultrasonically cleaning the mixture for 2 times by adopting the absolute ethyl alcohol, drying and sterilizing the mixture to obtain a porous section;
and 2, dissolving 1.5kg of tris (hydroxymethyl) aminomethane in 90kg of water, adjusting the pH value of the system to be 8-8.4 by adopting hydrochloric acid with the concentration of 1mol/L, adding 1.5kg of tannic acid, uniformly stirring, immersing the porous section in the hydrochloric acid, carrying out ultrasonic treatment for 1.5h, wherein the ultrasonic power is 350W, the ultrasonic temperature is 45 ℃, taking out, cleaning for 2 times by using deionized water, and drying to obtain the wound hemostasis treating agent.
The wound hemostatic treatment agents obtained in example 5 and comparative examples 1-2 were subjected to comparative tests, specifically as follows:
(1) water absorption test
Accurately weighing 1.0g of each group of samples, placing the samples into a beaker, adding about 1L of deionized water, fully absorbing water at room temperature until the porous microspheres are saturated with water, and filtering unadsorbed water by using a cloth bag until the water drops basically. And (3) measuring the weight of the microsphere gel after full water absorption, and calculating the water absorption times according to the following formula:
water absorption multiple ═ m-m 0 )/m 0
m 0 : mass of porous microspheres before water absorption, g; m: mass of microsphere gel after water absorption, g.
From the above table it can be seen that: the treatment agent for rapidly promoting wound hemostasis obtained in example 5 had the highest water absorption capacity. In comparative example 1, sodium alginate coordination and calcium chloride ethanol solution are not adopted for ion exchange, so that the porous section bar does not have a double interpenetrating network structure, and the water absorption effect is slightly inferior.
(2) Blood coagulation test
The sample of each group (0.1 g) was mixed with 0.2mL of whole blood, and the content of unsolidified hemoglobin before and after mixing was measured by ultraviolet light, whereby the coagulated hemoglobin fraction, that is, the whole blood coagulation fraction was calculated. The results are as follows:
| coagulation rate of whole blood% | |
| Example 5 | 92.3 |
| Comparative example 1 | 88.5 |
| Comparative example 2 | 54.3 |
(3) Hemostasis test of rats
SD rats were used as subjects, and 4 groups were set up, with 3 replicates in each group, with 3 SD rats in each replicate. Each group of experimental rats was subjected to tail amputation and liver puncture to create an animal bleeding model, after bleeding, bleeding was stopped with the wound hemostatic treatment agents obtained in example 5 and comparative examples 1-2, respectively, and the blank control group was left untreated, and bleeding time was recorded as follows:
the blood coagulation experiment and the rat hemostasis experiment show that: the whole blood coagulation rate of the treatment agent for rapidly promoting wound hemostasis obtained in example 5 is highest, and the blood coagulation time is shortest.
The applicant believes that: on one hand, the invention increases the concentration of the blood coagulation factor in the blood through the high water absorption multiple of the porous section bar to promote the blood coagulation of the wound, and on the other hand, the blood platelet with negative electricity is activated through the nanoparticle mixed liquid through coulomb force to induce the blood platelet aggregation to accelerate the blood coagulation process.
(4) Tensile fracture test
After drying, each group of samples was cut into strips of 1.5cm × 8cm, and a tensile fracture test was performed on each strip using a universal tester, with the following results:
| tensile breaking strength, Mpa | Elongation at break,% | |
| Example 5 | 116.1 | 4.83 |
| Comparative example 1 | 57.4 | 5.57 |
| Comparative example 2 | 98.5 | 4.22 |
From the above table it can be seen that: the treatment agent for rapidly promoting wound hemostasis obtained in example 5 has the highest tensile break strength. In the comparative example 1, sodium alginate coordination and calcium chloride ethanol solution are not adopted for ion exchange, so that the wound hemostasis treating agent does not have a double interpenetrating network structure, the mechanical property is obviously inferior to that of the example 5, and the wound can not be effectively blocked and stopped.
The above description is only for the preferred embodiment of the present invention, but the scope of the present invention is not limited thereto, and any person skilled in the art should be considered to be within the technical scope of the present invention, and the technical solutions and the inventive concepts thereof according to the present invention should be equivalent or changed within the scope of the present invention.
Claims (10)
1. A preparation method of a treating agent for rapidly promoting wound hemostasis is characterized by comprising the following steps:
step 1, uniformly mixing a chitosan solution, a polyvinyl alcohol/sodium alginate composite aqueous solution and a catalyst, adding glutaraldehyde to react for 1-3h at 50-60 ℃ under a stirring state, adding absolute ethyl alcohol to continue stirring, adjusting a system to be neutral, adding the mixture into a mold, freezing for 1-2h at-20 to-40 ℃, recovering to room temperature, soaking in a calcium chloride ethanol solution for 1-4h, ultrasonically cleaning, drying and sterilizing to obtain a porous section;
and 2, dissolving the tris (hydroxymethyl) aminomethane in water, adjusting the pH value of the system to 8-8.4, adding tannic acid, uniformly stirring, immersing the porous section in the solution, performing ultrasonic treatment for 1-2h, performing ultrasonic power of 300-400W and ultrasonic temperature of 40-50 ℃, cleaning, drying, immersing the porous section in the nanoparticle mixed solution, standing at room temperature for 10-20h, taking out and drying to obtain the treating agent for rapidly promoting wound hemostasis.
2. The method for preparing a treatment agent for rapidly promoting wound hemostasis as claimed in claim 1, wherein in step 1, the chitosan solution is prepared by adding chitosan into an acidic solution and uniformly stirring.
3. The method for preparing a treatment agent for rapidly promoting wound hemostasis according to claim 2, wherein the acidic solution is an aqueous solution of at least one of acetic acid, citric acid or malic acid.
4. The method for preparing a treating agent for rapidly promoting wound hemostasis as claimed in claim 1, wherein in step 1, the polyvinyl alcohol/sodium alginate composite aqueous solution is prepared by adding vinyl alcohol and sodium alginate into water and stirring until completely dissolved.
5. The preparation method of the treating agent for rapidly promoting wound hemostasis according to claim 1, wherein in the step 1, the mass ratio of chitosan, polyvinyl alcohol, sodium alginate, catalyst and glutaraldehyde is 10-20: 5-15: 1-5: 0.01-0.1: 1-2.
6. The method for preparing a treating agent for rapidly promoting wound hemostasis as claimed in claim 1, wherein in step 1, the catalyst is at least one of hydrochloric acid, sulfuric acid, acetic acid and phosphoric acid in step 1.
7. The preparation method of the treating agent for rapidly promoting wound hemostasis according to claim 1, wherein in the step 2, the mass ratio of the tris, the tannic acid and the water is 1-2: 1-2: 80-100.
8. The method for preparing a treatment agent for rapidly promoting wound hemostasis as claimed in claim 1, wherein in step 2, the nanoparticle mixed solution is prepared by adding ursodeoxycholic acid and polyethyleneimine into dimethyl sulfoxide, mixing uniformly, and then dialyzing in deionized water.
9. The method for preparing a treatment agent for rapidly promoting wound hemostasis as defined in claim 1, wherein in step 2, the particle diameter of the nanoparticles in the nanoparticle mixed solution is 150-200nm, and the Zeta potential is 60-70 mV.
10. A treatment agent for rapidly promoting hemostasis of wounds, which is prepared by the preparation method of the treatment agent for rapidly promoting hemostasis of wounds according to any one of claims 1 to 9.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210397809.7A CN114949332B (en) | 2022-04-15 | 2022-04-15 | Treating agent for rapidly promoting wound hemostasis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210397809.7A CN114949332B (en) | 2022-04-15 | 2022-04-15 | Treating agent for rapidly promoting wound hemostasis and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114949332A true CN114949332A (en) | 2022-08-30 |
| CN114949332B CN114949332B (en) | 2023-07-07 |
Family
ID=82977528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210397809.7A Active CN114949332B (en) | 2022-04-15 | 2022-04-15 | Treating agent for rapidly promoting wound hemostasis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114949332B (en) |
Citations (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101342381A (en) * | 2008-08-29 | 2009-01-14 | 暨南大学 | Preparation method for anti-inflammation adhesion-proof hemostatic sponge |
| CN102108172A (en) * | 2010-01-20 | 2011-06-29 | 威海世创新材料科技有限公司 | Chitosan/polyvinyl alcohol (PVA) porous composite material and preparation method thereof |
| CN103463667A (en) * | 2013-05-07 | 2013-12-25 | 哈尔滨工程大学 | Preparation method of nanosilver-carried calcium alginate antibiotic medical dressing |
| CN104069536A (en) * | 2014-07-11 | 2014-10-01 | 江苏开源康达医疗器械有限公司 | Method for preparing sodium alginate-chitosan nano-grade medical dressing |
| CN104307031A (en) * | 2014-11-10 | 2015-01-28 | 刘维峰 | Preparation method and usage of external use skin repair material |
| CN104491913A (en) * | 2014-12-13 | 2015-04-08 | 天津宜耀科技有限公司 | Method for preparing silkworm chitosan composite haemostatic material |
| CN105816909A (en) * | 2016-05-10 | 2016-08-03 | 北京科技大学 | Method for preparing high-elasticity high-absorbency hemostatic and bacteriostatic expansive sponge |
| CN106822987A (en) * | 2017-04-07 | 2017-06-13 | 广东海洋大学 | A kind of porous ball hemostatic material preparation method of shitosan alginate |
| CN107308488A (en) * | 2017-06-06 | 2017-11-03 | 广西达庆生物科技股份有限公司 | A kind of preparation method of the styptic powder of chloride containing calcium and sodium alginate |
| CN107693836A (en) * | 2017-09-30 | 2018-02-16 | 广东泰宝医疗科技股份有限公司 | A kind of antibacterial alginates bearing hydrocolloid dressing and preparation method thereof |
| US20180117212A1 (en) * | 2016-10-28 | 2018-05-03 | Guangdong Ocean University | Wound-healing and hemostatic sponge of squid ink polysaccharide/chitosan, preparation method and use thereof |
| KR20200037936A (en) * | 2018-10-02 | 2020-04-10 | 한림대학교 산학협력단 | Rapid photocuring bio-glue with adhesion, heamostatic and wound healing efficacy |
| CN111282016A (en) * | 2020-02-10 | 2020-06-16 | 中国药科大学 | Calcium alginate/thrombin composite hemostatic microsphere and preparation method thereof |
| CN112206342A (en) * | 2020-09-27 | 2021-01-12 | 广东泰宝医疗科技股份有限公司 | Alginate composite dressing and preparation method thereof |
| CN113134112A (en) * | 2021-06-22 | 2021-07-20 | 北京戎盾医疗科技有限公司 | Rapid imbibition expansion type composite compression hemostatic sponge and preparation method thereof |
| US20210252182A1 (en) * | 2018-08-27 | 2021-08-19 | Advamedica Inc. | Composite dressings, manufacturing methods and applications thereof |
| CN113694247A (en) * | 2021-08-09 | 2021-11-26 | 北京化工大学 | Preparation method of multifunctional composite hemostatic sponge |
-
2022
- 2022-04-15 CN CN202210397809.7A patent/CN114949332B/en active Active
Patent Citations (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101342381A (en) * | 2008-08-29 | 2009-01-14 | 暨南大学 | Preparation method for anti-inflammation adhesion-proof hemostatic sponge |
| CN102108172A (en) * | 2010-01-20 | 2011-06-29 | 威海世创新材料科技有限公司 | Chitosan/polyvinyl alcohol (PVA) porous composite material and preparation method thereof |
| CN103463667A (en) * | 2013-05-07 | 2013-12-25 | 哈尔滨工程大学 | Preparation method of nanosilver-carried calcium alginate antibiotic medical dressing |
| CN104069536A (en) * | 2014-07-11 | 2014-10-01 | 江苏开源康达医疗器械有限公司 | Method for preparing sodium alginate-chitosan nano-grade medical dressing |
| CN104307031A (en) * | 2014-11-10 | 2015-01-28 | 刘维峰 | Preparation method and usage of external use skin repair material |
| CN104491913A (en) * | 2014-12-13 | 2015-04-08 | 天津宜耀科技有限公司 | Method for preparing silkworm chitosan composite haemostatic material |
| CN105816909A (en) * | 2016-05-10 | 2016-08-03 | 北京科技大学 | Method for preparing high-elasticity high-absorbency hemostatic and bacteriostatic expansive sponge |
| US20180117212A1 (en) * | 2016-10-28 | 2018-05-03 | Guangdong Ocean University | Wound-healing and hemostatic sponge of squid ink polysaccharide/chitosan, preparation method and use thereof |
| CN106822987A (en) * | 2017-04-07 | 2017-06-13 | 广东海洋大学 | A kind of porous ball hemostatic material preparation method of shitosan alginate |
| CN107308488A (en) * | 2017-06-06 | 2017-11-03 | 广西达庆生物科技股份有限公司 | A kind of preparation method of the styptic powder of chloride containing calcium and sodium alginate |
| CN107693836A (en) * | 2017-09-30 | 2018-02-16 | 广东泰宝医疗科技股份有限公司 | A kind of antibacterial alginates bearing hydrocolloid dressing and preparation method thereof |
| US20210252182A1 (en) * | 2018-08-27 | 2021-08-19 | Advamedica Inc. | Composite dressings, manufacturing methods and applications thereof |
| KR20200037936A (en) * | 2018-10-02 | 2020-04-10 | 한림대학교 산학협력단 | Rapid photocuring bio-glue with adhesion, heamostatic and wound healing efficacy |
| CN111282016A (en) * | 2020-02-10 | 2020-06-16 | 中国药科大学 | Calcium alginate/thrombin composite hemostatic microsphere and preparation method thereof |
| CN112206342A (en) * | 2020-09-27 | 2021-01-12 | 广东泰宝医疗科技股份有限公司 | Alginate composite dressing and preparation method thereof |
| CN113134112A (en) * | 2021-06-22 | 2021-07-20 | 北京戎盾医疗科技有限公司 | Rapid imbibition expansion type composite compression hemostatic sponge and preparation method thereof |
| CN113694247A (en) * | 2021-08-09 | 2021-11-26 | 北京化工大学 | Preparation method of multifunctional composite hemostatic sponge |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114949332B (en) | 2023-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110755678B (en) | 3D printing antibacterial hydrogel wound dressing based on green in-situ reduction | |
| CN107349459B (en) | A kind of glucan base hemostatic and antibacterial promoting healing material and preparation method thereof | |
| ZA200605131B (en) | Wound dressing and method for controlling severe, life threatening bleeding | |
| WO2005062889A2 (en) | Wound dressing and method for controlling severe, life- threatening bleeding | |
| CN108853570B (en) | Hemostatic sponge and preparation method thereof | |
| WO2018192562A1 (en) | Hemostatic material and preparation method therefor | |
| CN111450308A (en) | Multifunctional hemostatic sponge and preparation method and application thereof | |
| JP2007197649A (en) | Sponge comprised of polysaccharide material | |
| DE1811290C3 (en) | Process for the production of collagen fiber braids in the form of felt-like membranes or sponge-like layers | |
| CN113663120B (en) | Hemostatic sponge cushion core and preparation method thereof | |
| KR102645889B1 (en) | Hemostatic fabric containing trypsin and method for manufacturing the same | |
| CN114949332B (en) | Treating agent for rapidly promoting wound hemostasis and preparation method thereof | |
| CN107349464B (en) | Preparation method of novel medical hemostatic gel dressing | |
| CN109731128B (en) | Absorbable and degradable biocompatible hemostatic material and preparation method thereof | |
| CN113134112B (en) | Rapid imbibition expansion type composite compression hemostatic sponge and preparation method thereof | |
| CN116999607A (en) | Self-gelling quick hemostatic powder and preparation method and application thereof | |
| CN103480038B (en) | Preparation method for chitosan/hydroxyapatite composite hydrogel | |
| KR20210000127A (en) | Hemostatic composition having improved mechanical strength and absorptiveness for effeecitve hemostasis | |
| CN113975456B (en) | Method for preparing chitin/glucan composite hemostatic sponge from pleurotus eryngii sporocarp | |
| CN111760066B (en) | Hemostatic gel and preparation method and application thereof | |
| CN113384740A (en) | Preparation method of ion/chemical double-crosslinking hemostatic antibacterial gel sponge | |
| CN113750287A (en) | Water-soluble hemostatic sponge and preparation method thereof | |
| Liu et al. | Corn stalk modified chitin composite sponge for effective hemostasis and promoting wound healing | |
| CN112870430A (en) | Composite gel hemostatic powder based on natural polysaccharide, and preparation method and application thereof | |
| Xu et al. | Hemostatic effect of macroporous polysaccharides composite hemostatic materials on small-artery severed injury |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |